NERLYNX – Breast Cancer Treatment [transcript] [audio]
Key Takeaways
- Key Insight: Guest: Frankie Ann Holmes, MD Presenter: Neal Howard Guests Bio: Dr.
- Clinical Perspective: Holmes is board certified in internal medicine and also medical oncology.
- Why It Matters: This discussion provides healthcare professionals with actionable insights relevant to clinical practice and patient care.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
Guest: Frankie Ann Holmes, MD
Presenter: Neal Howard
Guests Bio: Dr. Holmes is board certified in internal medicine and also medical oncology. My professional career has involved the treatment and research for the cure of breast cancer. At MD Anderson, I completed my cancer training and joined the Faculty of Breast Medical Oncology. At MD Anderson, I performed the first clinical trial of paclitaxel (Taxol) resulting in approval for breast cancer. After 15 years at MD Anderson, I joined Texas Oncology/The US Oncology Network and the Breast Cancer Research Committee. I was the principal investigator for the clinical trial that led to the approval of pegfilgrastim (Neulasta) for prevention of low white blood cells from chemotherapy. I have continued as an active member of the Breast Cancer Research Committee with The US Oncology Network.
Segment overview: Frankie Ann Holmes, MD, discusses the latest in breast cancer research and the recently approved NERLYNX for early-stage HER2-positive breast cancer.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
